mtDNA Damage in Alzheimer's Disease (AD)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- Biological marker of Alzheimer's disease
研究概览
简要总结
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Alzheimer's Disease Patients:
- •50 years and older
- •AD patient who is seen at the Memory Disorders Clinic
- •AD diagnosis
- •Non smoking
- •No cancer treatment in the last 5 years
- •Informed consent from the patient or the patient's legally authorized representative (LAR)
- •Patient and/or LAR able to read and speak English
- •Healthy Control Participants:
- •50 years and older
- •Non smoking
- •No cancer treatment in the last 5 years
- •Age matched to AD subject
- •Able to read and speak English
排除标准
- •Alzheimer's Disease Patients:
- •Known additional neurological disease
- •Healthy Control Participants:
- •Neurological degenerative diseases (such as Parkinson's, Alzheimer's or Huntington's)
结局指标
主要结局
Biological marker of Alzheimer's disease
时间窗: Day 1
Test for blood biological marker of Alzheimer's disease, mtDNA damage
次要结局
未报告次要终点